Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...
Here are highlights from Wednesday’s Analyst Blog:
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discu ...
Vertex Pharmaceuticals: Strong Buy Rating Driven by Journavx Approval and Market Expansion ...
Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Google releases Gemini 2.0 Flash for AI Studio and Vertex AI
Gemini 2.0 Flash is the base model that powers the free version of Gemini. It replaces Gemini 1.5 Flash which was released ...
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating ...
Her Zindagi Hindi9 小时
Gemini 2.0: New Features, Details, How To Use, and More
Google’s Gemini 2.0 is here, bringing improved performance, smarter reasoning, and new models like Flash-Lite and Pro for ...
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...